Literature DB >> 12505118

The vulnerable plaque and acute coronary syndromes.

Roberto Corti1, Michael E Farkouh, Juan Jose Badimon.   

Abstract

The interaction between the vulnerable atherosclerotic plaque and thrombus formation, a process referred to as atherothrombosis, is the cornerstone of acute coronary syndromes. Advances in noninvasive imaging have helped to identify novel approaches to plaque stabilization, with the potential to prevent plaque rupture, including lifestyle modification and dietary adjustments, as well as pharmacologic interventions such as statins. Following an acute coronary event, strategies combining mechanical and pharmacologic therapies provide considerable advances in prevention of subsequent cardiac events. Pharmacologic strategies to prevent and treat thrombotic complications related to acute coronary syndromes have been developed to dissolve preformed thrombi and to inhibit thrombogenesis. These regimens focus on inhibiting thrombin, preventing thrombi generation, blocking the initiation of coagulation, inhibiting platelet activation, and increasing fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505118     DOI: 10.1016/s0002-9343(02)01344-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Targeted probes for cardiovascular MRI.

Authors:  Ritika Uppal; Peter Caravan
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

Review 2.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.

Authors:  Joakim Alfredsson; Matthew T Roe
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.606

4.  Carotid endarterectomy remains the standard of care, even in high-risk surgical patients.

Authors:  Tamer N Boules; Mary C Proctor; Ahmad Aref; Gilbert R Upchurch; James C Stanley; Peter K Henke
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  An ultrasound contrast agent targeted to P-selectin detects activated platelets at supra-arterial shear flow conditions.

Authors:  Felix Guenther; Constantin von zur Muhlen; Elisa A Ferrante; Sebastian Grundmann; Christoph Bode; Alexander L Klibanov
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

6.  Baseline clinical characteristics and midterm prognosis of STE-ACS and NSTE-ACS patients with normal coronary arteries.

Authors:  Lukasz Mazurkiewicz; Zofia T Bilinska; Mariusz Kruk; Andrzej Ciszewski; Jacek Grzybowski; Adam Witkowski; Witold Ruzyllo
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

7.  In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in mice.

Authors:  Dominik von Elverfeldt; Constantin von zur Muhlen; Kristina Wiens; Irene Neudorfer; Andreas Zirlik; Mirko Meissner; Peg Tilly; Anne-Laure Charles; Christoph Bode; Karlheinz Peter; Jean-Etienne Fabre
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  Is the WHI relevant to HRT started in the perimenopause?

Authors:  S Mitchell Harman; Eliot A Brinton; Thomas Clarkson; Christopher B Heward; Harvey S Hecht; Richard H Karas; Debra R Judelson; Frederick Naftolin
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

9.  Acute coronary disease Athero-Inflammation: Therapeutic approach.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2003-06-20

10.  Risk factors in coronary atherosclerosis athero-inflammation: the meeting point.

Authors:  Raul Altman
Journal:  Thromb J       Date:  2003-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.